Clinical Trial Update: Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC [Phase 3]

View source ↗

Summary

A4250 (odevixibat) was studied in a long-term Phase 3 trial in children with Progressive Familial Intrahepatic Cholestasis. The results assessing safety and eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Familial Intrahepatic Cholestasis

Drugs mentioned

• A4250 (odevixibat)

Snippet

Sponsor: Albireo, an Ipsen Company | Conditions: Progressive Familial Intrahepatic Cholestasis | Phase 3 | Status: COMPLETED | Results posted: 2025-07-10